<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908528</url>
  </required_header>
  <id_info>
    <org_study_id>Alpha-Lipoic Acid</org_study_id>
    <nct_id>NCT03908528</nct_id>
  </id_info>
  <brief_title>Alpha-Lipoic Acid in Breast Cancer Patients</brief_title>
  <official_title>Role of Alpha-Lipoic Acid Against Chemotherapy Induced Toxicities in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      • Investigate the ability of alpha lipoic acid to counter act anthracycline associated&#xD;
      cardiotoxicity and cumulative taxens-related PN in patients with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty breast cancer patients with stage from stage I to stage III will be involved in this&#xD;
      study. Staging is done according to the American joint committee on cancer: TNM staging of&#xD;
      breast cancer.&#xD;
&#xD;
        -  All participants will be recruited from Tanta Oncology Center. The study will be&#xD;
           approved by Research Ethics Committee of Damanhour University. All participants will&#xD;
           give their consent.&#xD;
&#xD;
        -  All 64 patients will be scheduled to receive 4 cycles of AC: cycled every 21 days&#xD;
           followed by weekly cycle of taxol for 12 weeks.&#xD;
&#xD;
      Patients will be classified as follow:&#xD;
&#xD;
        -  Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12&#xD;
           weeks plus placebo.&#xD;
&#xD;
        -  Group two: 32 patients will receive the same regimen as group 1 in addition to oral 600&#xD;
           mg alpha lipoic acid (ALA) once daily.&#xD;
&#xD;
      All patients will be submitted to:&#xD;
&#xD;
        1. Full patient history and clinical examination.&#xD;
&#xD;
        2. Venous blood will be collected before the first cycle of chemotherapy and after the last&#xD;
           cycle of chemotherapy.&#xD;
&#xD;
      1- Cardio-toxcity assessment: i. Echo-cardiogram. ii. Troponin I. iii. The Brain Natriuretic&#xD;
      Peptide (BNP). 2- Neurotoxicity assessment: i. National Cancer Institute common Terminology&#xD;
      criteria for Adverse Effect grading: NCI-CTCAE version 4.0.&#xD;
&#xD;
      ii. Neurotoxicity questionnaire from the validated Functional Assessment of cancer&#xD;
      therapy/gynecologic oncology group taxane specific neurotoxicity questionnaire: FACT-Taxane.&#xD;
&#xD;
      iii. Neurotensin 3- Oxidative stress and inflammatory markers: i. Malondialdehyde (MDA). ii.&#xD;
      TNF-alpha&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind study, Patients will be classified as follow:&#xD;
Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus placebo.&#xD;
Group two: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus oral 600 mg alpha lipoic acid (ALA) once daily.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiotoxcity assessment</measure>
    <time_frame>six months</time_frame>
    <description>serum Brain Natriuretic Peptide (BNP) level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurotoxicity assessment</measure>
    <time_frame>six months</time_frame>
    <description>Neurotensin level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oxidative stress and inflammatory markers</measure>
    <time_frame>six months</time_frame>
    <description>TNF-alpha level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MDA</measure>
    <time_frame>six months</time_frame>
    <description>Malondialdehyde</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Chemotherapeutic Toxicity</condition>
  <arm_group>
    <arm_group_label>Chemotherapy plus Placebo for six Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy plus alpha lipoic acid for six Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Group two: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks in addition to oral 600 mg alpha lipoic acid (ALA) once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)</intervention_name>
    <description>600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..</description>
    <arm_group_label>Chemotherapy plus alpha lipoic acid for six Months</arm_group_label>
    <other_name>Thiotacid 600 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)</intervention_name>
    <description>Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.</description>
    <arm_group_label>Chemotherapy plus Placebo for six Months</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients age ≥ 18 and &lt; 70 years old with confirmed stage from stage I to stage&#xD;
             III.&#xD;
&#xD;
          2. No evidence of metastases at initial assessment.&#xD;
&#xD;
          3. Patients has to have a good performance status (ECOG 0-2) according to Eastern&#xD;
             Cooperative Oncology Group (ECOG) score.&#xD;
&#xD;
          4. Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109/L,&#xD;
             platelet count ≥ 100 × 109/L, and hemoglobin level ≥ 10g/dL).&#xD;
&#xD;
          5. Patients with adequate liver function (serum creatinine &lt; 1.5 mg/dL) and adequate&#xD;
             renal function (serum creatinine &lt; 1.5 mg/dL, creatinine clearance (CrCl) &gt; 45&#xD;
             ml/min).&#xD;
&#xD;
          6. Either pre operative or post operative chemotherapy are allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of metastases at initial assessment.&#xD;
&#xD;
          2. Pregnancy or breast-feeding patients.&#xD;
&#xD;
          3. Prior exposure to neurotoxic chemotherapy was not allowed (no carboplatin,&#xD;
             vincristine, vinblastine, paclitaxel, or docetaxol ) for 6 months prior study&#xD;
             treatment.&#xD;
&#xD;
          4. Clinical evidence of serious cardiac illness (myocardial dysfunctional, angina&#xD;
             pectoris requiring anti-angina medication, poorly controlled hypertension, and&#xD;
             uncontrolled arrhythmias).&#xD;
&#xD;
          5. Patients with a reduced cardiac output with a left ventricular ejection fraction&#xD;
             (LVEF) ejection fraction &lt; 50%.&#xD;
&#xD;
          6. Patients who had evidence of pre-existing peripheral neuropathy resulting from another&#xD;
             reason (diabetes).&#xD;
&#xD;
          7. Patients with a history of allergy to alpha-lipoic acid.&#xD;
&#xD;
          8. Concomitant use of multivitamins (vitamin E), opioids, anticonvulsants, tricyclic&#xD;
             antidepressants, other neuropathic pain medication modifying agents (e.g., gabapentin,&#xD;
             lamotrigine, carbamazepine, phenytoin, or tricyclic antidepressants) are not allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reham A Elshafiey, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta Oncology Center</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Kapoor S. The Anti-neoplastic Effects of Alpha-Lipoic Acid: Clinical Benefits in System Tumors besides Lung Carcinomas. Korean J Thorac Cardiovasc Surg. 2013 Apr;46(2):162-3. doi: 10.5090/kjtcs.2013.46.2.162. Epub 2013 Apr 9.</citation>
    <PMID>23614108</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>alpha-lipoic acid</keyword>
  <keyword>taxol</keyword>
  <keyword>Adriamycin</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>breast cancer</keyword>
  <keyword>Brain Natriuretic Peptide (BNP).</keyword>
  <keyword>Neurotensin</keyword>
  <keyword>TNF-alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

